Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The drug targets GLP-1, GIP and glucagon hormones, unlike existing treatments that target one or two of these hormones. Tirzepatide, the active ingredient in Lilly's Zepbound, mimics GLP-1 and GIP, while Novo Nordisk's semaglutide in Wegovy mimics only GLP-1. The drug represents the next pillar of Lilly's obesity portfolio after Zepbound and its newly launched pill Foundayo. Related articlesLilly to file for next-gen obesity drug approval in early 2027Exclusive: Axiom CEO on Hong Kong IPO plans, path to public marketsAlphabet, Reddit added to Wedbush's Best Ideas List